Novatek International is pleased to announce that Quanterix in Lexington, MA USA has chosen Nova-Stability from the Nova-LIMS Product Suite for automating and managing their stability process. Nova-Stability’s powerful functionality is backed by hundreds of user requirements incorporating the in-depth knowledge of numerous experts in the best quality practices driving higher adoption and greater operational efficiency to our clients.
Novatek International is pleased to welcome Quanterix to our family of many other prestigious Nova-Stability clientele such as Hospira, Inc., Merck & Co., Inc., Pfizer, Sanofi-Aventis, Paxvax, Novartis, Medline, Ranbaxy, Biovest International, Inc., Jubilant HollisterStier, Amoun Pharmaceuticals, Virbac USA, and Bayer.
Our services are second to none and our implementation and validation timelines easily beat the industry expectations every time! We invite you to evaluate our applications for yourself and find out why Novatek’s Suite of Quality Management software has become the industry standard. Come see us at booth 650 at the 2015 Annual AAPS Exposition Oct. 25-29 in sunny Orlando, FL to learn more about Nova-Stability!
About Quanterix:
Quanterix offers an ultra-sensitive diagnostic platform capable of measuring individual proteins at concentrations 1000 times lower than the best immunoassays available today. The Single Molecule Array (Simoa™) technology at the heart of the platform enables the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications to address significant unmet needs in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more. Quanterix is a venture capital backed company and the exclusive licensee of a broad intellectual property portfolio initially developed at Tufts University by Dr. David Walt, scientific founder of Quanterix and Illumina (NASDAQ: ILMN).
